Therefore, activating PD-L1-specific T cells by vaccines can directly target immunosuppressive pathways in the tumor microenvironment, modulate the immune microenvironment and potentially alter the tolerance of the immune system to tumor antigens41. The gene discussed is CD274; the disease is neoplasm.